A reduced-intensity hematopoietic stem cell transplantation (RIST) regimen was developed to induce immunosuppression to facilitate the engraftment of donor cells. However, there have been concerns that the incidence of opportunistic infection may increase after this procedure. To address this problem, we retrospectively analyzed the medical records of 24 RIST recipients who were treated over a recent 16-month period for comparison with 31 recipients of conventional allogeneic transplantation (CST). The RIST regimen consisted of cladribine (0.66 mg/kg), busulfan (8 mg/kg), and rabbit anti-thymocyte globulin (ATG; 5-10 mg/kg). All of the patients received allogeneic peripheral blood stem cells from an HLA-identical or one-locus mismatched related donor. Although the incidence of positive CMV antigenemia was comparable between the two groups (58% vs 68%), RIST patients developed positive antigenemia significantly sooner than did CST patients (P = 0.01) and showed higher initial and maximum antigenemia values (P = 0.026 and P = 0.003, respectively). These findings may suggest that immune recovery against CMV was delayed after our RIST procedure, but this did not directly translate into an increase in clinically significant CMV disease. Early therapeutic intervention with ganciclovir might play a role in preventing the progression of early CMV infection to CMV disease. Bone Marrow Transplantation ( duction of reduced-intensity hematopoietic stem cell transplantation (RIST) should further facilitate the use of HSCT in a wider population of patients.
duction of reduced-intensity hematopoietic stem cell transplantation (RIST) should further facilitate the use of HSCT in a wider population of patients. [1] [2] [3] [4] [5] However, several problems inherent in this novel procedure still need to be resolved. One potential problem is the possible delay of immune reconstitution after RIST. Since the RIST regimen is primarily based on the concept of intensifying immunosuppression to enhance engraftment of donor cells rather than cytoreduction, it is very likely that opportunistic infection will increase during this procedure. To address this problem, we surveyed the clinical characteristics of cytomegalovirus (CMV) infection, a hallmark of opportunistic infection, in our transplant cohort. The incidence and levels of CMV antigenemia were compared between RIST and conventional HSCT (CST) procedures.
Patients and methods

Patients
We retrospectively analyzed the medical records of 55 consecutively registered CMV-seropositive patients who had undergone allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-identical or one-locus mismatched relative at the National Cancer Center Hospital between June 1999 and October 2000. Thirty-one patients underwent CST, whereas 24 underwent RIST for reasons which precluded CST, ie age over 50 years or organ dysfunction. Patient characteristics are shown in Table 1 . The patients could be classified into two populations: heavily treated and less heavily treated, based on the intensity of preceding chemotherapy or the nature of the underlying disorder, as follows. The 'heavily pretreated' group included acute leukemias and non-Hodgkin's lymphoma, whereas the 'less heavily treated' group included chronic leukemias, myelodysplastic syndrome, severe aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Among those with solid tumors, two were heavily and four were less heavily pretreated. The patients' backgrounds were essentially identical between the RIST and CST groups. 
Transplantation procedures and supportive therapies
The RIST regimen consisted of cladribine (0.11 mg/kg from day −10 to day −5), busulfan (4 mg/kg on days −6 and −5), and rabbit anti-thymocyte globulin (ATG; 2.5 mg/kg from day −4 to −1). 6 The dose of ATG was decreased to 2 days after stable engraftment was confirmed in the initial four patients. In the CST group, 18 patients received fractionated total body irradiation (TBI) on 3 consecutive days (2 Gy twice daily) combined with cyclophosphamide (Cy; 60 mg/kg for 2 days) or melphalan (110 mg/m 2 ). The remaining 13 patients received oral busulfan 4 mg/kg for 4 days and Cy 60 mg/kg for 2 days. All of the patients received G-CSF from day +6 after transplantation until they achieved an absolute neutrophil count (ANC) of more than 1.0 ϫ 10 9 /l. Hemoglobin was maintained at a level over 7 g/dl and the platelet count was maintained over 20 × 10 9 /l with filtered and irradiated blood products. Prophylaxis against GVHD was performed with cyclosporine (CsA) alone in RIST, while CsA and shortterm methotrexate (MTX) were used in CST. Patients who developed grades II-IV acute GVHD were treated with methylprednisolone at 1-2 mg/kg/day i.v. Antibacterial and antifungal prophylaxis consisted of ciplofloxacin at 600 mg/day and fluconazole at 200 mg/day. Prophylaxis against herpes simplex virus was performed with acyclovir at 1000 mg/day orally or 750 mg/day i.v. from days −7 to 35, followed by long-term low-dose (400 mg/day) oral daily administration until the end of immunosuppressive therapy. Pneumocystis carinii prophylaxis included trimethoprim/sulfamethoxazole for 14 days before transplantation and twice weekly after engraftment.
CMV antigenemia assay
CMV antigenemia assay was performed at least once a week after engraftment by a modified method as described previously. 7 Briefly, peripheral blood leukocytes were isolated by dextran sedimentation and cytocentrifuged on to glass slides. The slides were then fixed with acetone and stained by the direct immunoperoxidase method using the monoclonal antibody, HRP-C7 (Teijin Ltd, Tokyo, Japan), which binds CMV immediate-early antigen. Under light microscopy, the degree of antigenemia was determined as the number of positive cells per 50 000 leukocytes. Highlevel antigenemia was defined as a positive result with 10 or more positive cells per 50 000 cells and low-level antigenemia was the presence of less than 10 positive cells.
Pre-emptive therapy for CMV disease
We performed risk-adapted pre-emptive therapy as previously reported. 8 High-risk patients were defined as those who were transplanted from mismatched donors, those with grades II-IV acute GVHD, and those receiving methylprednisolone at a dose of more than 0.5 mg/kg. The remaining patients were considered to be low risk. When high-level antigenemia was disclosed in low-risk patients or five or more positive cells per 50 000 cells were detected in highrisk patients, ganciclovir was started at a dose of 5 mg/kg twice a day. Ganciclovir was given for at least a week until CMV antigenemia resolved. The initial dose of ganciclovir was decreased to 5 mg/kg/day after June 2000, when a protocol of pre-emptive therapy with reduced-dose ganciclovir was started. 9 In this protocol, the dose of ganciclovir was escalated to 5 mg/kg twice a day, when the antigenemia value increased with the initial dose of ganciclovir.
Statistical analysis
Differences in probabilities were evaluated with Fisher's exact test. Time to the documentation of first positive antigenemia was estimated by the Kaplan-Meier method and compared between the two groups using the log-rank test. To compare the mean levels of antigenemia, we used a ttest after logarithmic transformation of antigenemia values, assuming that the antigenemia values fitted a logarithmic normal distribution.
Results
Engraftment, acute GVHD and survival
All patients achieved engraftment. Seven (29%) in the RIST group and 12 (39%) in the CST group developed grades II-IV acute GVHD. Early transplant-related death within 100 days was observed in five patients each after RIST and CST, respectively. The causes of death in RIST group were acute GVHD in three, disseminated candidiasis in one, and bacteremia in one, whereas those in the CST group were fungal or bacterial pneumonia in three, acute GVHD in one, and hepatic veno-occlusive disease in one. 
Probability and the level of positive antigenemia
Fourteen patients (58%) in the RIST group and 21 (68%) in the CST group developed positive antigenemia before day 100 (P = 0.58), although none of the patients developed either early (before day 100) or late CMV disease. Among factors which have been reported as risk factors for CMV disease, only the development of grades II-IV GVHD significantly influenced the incidence of positive antigenemia ( Table 2 ). The time to the first appearance of positive antigenemia is shown in Figure 1 . Among patients who developed positive antigenemia, RIST patients developed it sooner than did CST patients (P = 0.01). Use of the RIST regimen significantly affected both the initial and maximum antigenemia values (Table 3 and Figure 2) . Notably, the difference between the groups was marked for the maximum antigenemia values (geometric mean value, 5.9 in CST vs 30.1 in RIST). 
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Pre-emptive therapy with ganciclovir
Twelve patients (39%) in the CST group and 11 (46%) in the RIST group received therapy with ganciclovir upon development of antigenemia. Antigenemia became negative within 2 weeks in six of the 12 patients in CST, and in four of the 11 patients in the RIST group. Eventually, antigenemia was resolved by ganciclovir in all but one patient in the RIST group who had ganciclovir-resistant antigenemia, which subsequently resolved with foscarnet.
Discussion
A novel approach with the RIST procedure should facilitate use of the allogeneic HSCT strategy to a wider population of patients, ie those with poor performance status or impaired organ function, or older patients. To obtain engraftment without myeloablation, RIST regimens use agents with potent immunosuppressive activities, such as fludarabine or ATG. This raises concerns of an increased incidence of opportunistic infectious complications, particularly CMV infection. Previously, Mohty et al 10 reported a high frequency of CMV infections after RIST using a regimen consisting of fludarabine, busulfan and ATG. A higher incidence of early and late CMV infection was also observed after a conditioning regimen with fludarabine, melphalan, and Campath 1H, a monoclonal anti-CD52 antibody. 11 On the other hand, Junghanss et al 12 observed a trend toward less CMV infection and disease after RIST using low-dose TBI with or without fludarabine. Graber et al 13 also showed a reduced incidence of CMV reactivation after conditioning with fludarabine and cyclophosphamide. Therefore, the risk of CMV infection appears to be influenced by the agents used in the RIST regimen. ATG and Campath 1H might be the most likely causative agents, since they affect both host and infused donorderived T cells, leading to prolonged immunosuppression; Chakrabarti et al 11 and our group 6 have reported delayed recovery of CD4 + cells after RIST using a regimen containing ATG or Campath 1H.
Our RIST regimen was similar to that reported by Mohty et al, 10 but there were at least two marked differences. First, they used bone marrow as a source of hematopoietic stem cells, whereas we exclusively performed PBSCT. It has been reported that the use of peripheral blood rather than bone marrow improves immune reconstitution against CMV.
14 Second, they used ATG at a higher dose (rabbit ATG 2.5 mg/kg for 4 days), while our dose was 2.5 mg/kg for 2 days, except for the initial four patients. ATG plays several roles in the RIST regimen. For example, it acts as prophylaxis against graft rejection and acute GVHD by suppressing both host and donor-derived T cells. On the other hand, it delays immune reconstitution after transplantation. The Dresden group reported their trial in RIST using fludarabine and busulfan without ATG, 15 in which positive CMV antigenemia was detected in only four of the 14 patients (29%) who received GVHD prophylaxis with CsA and mycophenolate mofetil. This supports the hypothesis that the use of ATG adversely affects the clinical course of CMV infection after RIST. Since it is unlikely that there is any biological difference between cladribine and fludarabine in facilitating CMV infection after RIST, the abovementioned differences in the RIST regimen are likely to be responsible for the higher incidence of early CMV infection reported in Mohty's study compared to ours (65% vs 42% before day 45). In this study, the incidence of positive antigenemia was comparable between the RIST and CST groups. However, both the initial positive and maximum antigenemia values were higher in RIST, suggesting the presence of impaired immune reconstitution after RIST, although this did not directly translate into an increased incidence of CMV disease.
In conclusion, earlier antigenemia at higher levels was observed after RIST than after CST, possibly because of delayed immune recovery against CMV. Nevertheless, this did not directly result in an increased incidence of clinically significant CMV disease. ATG appears to be the most likely causative agent for prolonged immunosuppression.
An effective RIST preparative regimen with or without ATG should be developed in a well-designed clinical trial, while evaluating the balance between risks of graft rejection, regimen-related toxicity, GVHD, and opportunistic infections. In this population, the benefit of early therapeutic intervention with ganciclovir based on close monitoring of the antigenemia status may have helped to prevent progression of early CMV infection to CMV disease.
